Amneal Pharmaceuticals (AMRX) Acquisitions (2018 - 2021)

Amneal Pharmaceuticals' Acquisitions history runs 3 years deep, the most recent figure standing at $72.7 million for Q4 2021.

• On a quarterly basis, Acquisitions changed N/A year-over-year to $72.7 million in Q4 2021; TTM through Dec 2022 was $72.7 million, a 50.38% decrease from a year earlier, with the FY2022 full-year figure at $84.7 million, down 42.19% from the prior year.
• Acquisitions fell to $72.7 million in Q4 2021 per AMRX's latest filing, from $73.8 million in the prior quarter.
• Across five years, Acquisitions topped out at $253.6 million in Q1 2020 and bottomed at -$2.6 million in Q3 2020.
• The 3-year median for Acquisitions is $38.0 million (2018), against an average of $66.9 million.
• Biggest YoY gain for Acquisitions was 19587.47% in 2021; the steepest drop was 19587.47% in 2021.
• Year by year, Acquisitions stood at $3.3 million in 2018, then sank by 179.76% to -$2.6 million in 2020, then surged by 2854.36% to $72.7 million in 2021.
• Per Business Quant, the three latest AMRX Acquisitions figures stand at $72.7 million (Q4 2021), $73.8 million (Q2 2021), and -$2.6 million (Q3 2020).